FLANDERS, Belgium and CAMBRIDGE, Mass., Oct. 19, 2022 (GLOBE NEWSWIRE) -- VIB, Flanders’ leading life sciences institute, and Surface Oncology (Nasdaq: SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced jointly the publication of a study entitled, “Structural basis of activation and antagonism of receptor signaling mediated by interleukin-27: Cell Reports,” in Cell Reports, a leading scientific journal. The study was a collaborative research effort between the Unit for Structural Biology at the VIB-University of Ghent Center for Inflammation Research and Surface Oncology.
ROTTERDAM, Netherlands and SAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics. Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB's expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx' strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.
ROTTERDAM, Netherlands and SAN DIEGO and GHENT, Belgium, Dec. 22, 2021 /PRNewswire/ -- Today, SkylineDx announced a 3-year strategic partnership with life sciences institute VIB for the evaluation and initiation of collaborative projects focused on molecular diagnostics. Under the agreement, SkylineDx and VIB will jointly evaluate opportunities regarding novel molecular diagnostics, combining VIB's expertise in state-of-the-art single-cell analysis and biomarker discovery applied to molecular pathology and precision diagnostics with SkylineDx' strategic expertise, global network of renowned clinical centers and physicians, and know-how in the development, market access and early commercialization of in vitro diagnostics.